https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-evercore-isi-4th-annual-healthconx-virtual
https://www.nasdaq.com/press-release/akero-presents-new-analysis-of-phase-2a-balanced-study-data-showing-additional
https://www.nasdaq.com/press-release/akero-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-2021-11
https://www.nasdaq.com/press-release/akero-therapeutics-receives-fda-fast-track-designation-for-efruxifermin-efx-for-the
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-h.c.-wainwright-5th-annual-nash-investor
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-morgan-stanley-virtual-global-healthcare
https://www.nasdaq.com/press-release/akero-therapeutics-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/akero-therapeutics-appoints-judy-chou-ph.d.-to-its-board-of-directors-2021-07-14
https://www.nasdaq.com/press-release/study-published-in-nature-medicine-shows-investigational-nash-drug-reduced-liver-fat
https://www.nasdaq.com/press-release/akero-therapeutics-presents-at-the-american-diabetes-associations-81st-scientific
https://www.nasdaq.com/press-release/akero-therapeutics-presents-analyses-at-the-2021-international-liver-congress-showing
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-efruxifermin-efx-results-showing-histologic-improvement
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-2021-05
https://www.nasdaq.com/press-release/akero-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/akero-therapeutics-appoints-yuan-xu-to-its-board-of-directors-2021-04-26
https://www.nasdaq.com/press-release/akero-therapeutics-announces-first-patient-randomized-for-dosing-in-phase-2b-study-of
https://www.nasdaq.com/press-release/akero-announces-positive-histological-improvements-in-cirrhotic-nash-f4-patients
https://www.nasdaq.com/press-release/akero-therapeutics-to-announce-new-data-from-an-evaluation-of-efruxifermin-efx-in
https://www.nasdaq.com/press-release/akero-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-2021
https://www.nasdaq.com/press-release/akero-therapeutics-to-participate-in-upcoming-virtual-healthcare-conferences-in-march
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-evercore-isi-3rd-annual-healthconx-virtual
https://www.nasdaq.com/press-release/akero-presents-additional-positive-data-from-phase-2a-balanced-study-demonstrating
https://www.nasdaq.com/press-release/akero-therapeutics-reports-third-quarter-2020-financial-results-2020-11-12
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-upcoming-conferences-in-november-2020-10-21
https://www.nasdaq.com/press-release/akero-therapeutics-receives-european-medicines-agency-priority-medicines-prime
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-data-from-phase-2a-balanced-study-of-efruxifermin-in
https://www.nasdaq.com/press-release/akero-therapeutics-completes-enrollment-of-cohort-of-cirrhotic-f4-patients-in-ongoing
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-h.c.-wainwrights-4th-annual-nash-virtual-investor
https://www.nasdaq.com/press-release/akero-therapeutics-to-continue-efruxifermin-development-with-innovative-adaptive
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-morgan-stanleys-18th-annual-global-healthcare
https://www.nasdaq.com/press-release/akero-therapeutics-reports-second-quarter-2020-financial-results-2020-08-12
https://www.nasdaq.com/press-release/research-published-in-cell-reports-medicine-highlights-potential-of-akero
https://www.nasdaq.com/press-release/akero-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and
https://www.nasdaq.com/press-release/akero-therapeutics-announces-pricing-of-public-offering-of-common-stock-2020-07-07
https://www.nasdaq.com/press-release/akero-therapeutics-announces-proposed-public-offering-of-common-stock-2020-07-06
https://www.nasdaq.com/press-release/akero-announces-strongly-positive-histological-data-across-all-efruxifermin-dose
https://www.nasdaq.com/press-release/akero-therapeutics-to-announce-new-data-from-nash-phase-2a-balanced-study-of-akr-001
https://www.nasdaq.com/press-release/akero-therapeutics-doses-first-patient-in-expansion-of-phase-2a-trial-in-nash-2020-06
https://www.nasdaq.com/press-release/akero-therapeutics-appoints-tom-heyman-to-its-board-of-directors-2020-06-10
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-2020-05
https://www.nasdaq.com/press-release/akero-therapeutics-reports-first-quarter-2020-financial-results-2020-05-13
https://www.nasdaq.com/press-release/all-akr-001-dose-groups-met-week-12-efficacy-endpoints-in-nash-phase-2a-balanced
https://www.nasdaq.com/press-release/akero-therapeutics-to-announce-results-for-week-12-efficacy-endpoints-from-nash-phase
https://www.nasdaq.com/press-release/akero-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-2020
https://www.nasdaq.com/press-release/akero-therapeutics-expands-phase-2a-trial-in-nash-to-include-cohort-of-cirrhotic
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-2020-j.p.-morgan-healthcare-conference-2020-01
https://www.nasdaq.com/press-release/akero-therapeutics-completes-enrollment-in-phase-2a-study-in-nash-2019-12-16
https://www.nasdaq.com/press-release/akero-therapeutics-to-present-at-the-jefferies-2019-london-healthcare-conference-2019
https://www.nasdaq.com/press-release/akero-therapeutics-reports-recent-highlights-and-third-quarter-2019-financial-results
